REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Regenxbio (RGNX) Climbs 30% Following New Positive Initial Efficacy Data From Affinity Duchenne Trial
March 5, 2024 7:42 AM ESTRegenxbio (NASDAQ: RGNX) Climbs 30% Following New Positive Initial Efficacy Data From Affinity Duchenne Trial
New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expressionPatient aged 12 years at dosing had expression level at 75.7% of controlEarly evidence of strength and... More